

Biomix Network LTD/INC (India/USA)

RECEPTOL®

Immunity Shield for unmet medical needs

Lab on a Chip

Handheld Detection of Virus, Bacteria, Bio/Nuclear Hazard, and Pollutants

Hospital on a Chip

AI based Knowledge Acquisition Tools (AIKAT)

Dr. Pawan Saharan, MS, PhD & Post Doc (WVU/Stanford)

drpawan@biomix.in, WA # 8291084108, www.biomix.in

Sustainable - Dairy Waste to life-saving drug

Glaxo & IPOS Global Market Research Yearly Estimates

USD 5.6 Billion - USA

USD 15 Billion - Worldwide

Estimated Time to Market : 3-6 months

Help 8 Billion Globally!




In Brief

- Founded in 1996 and registered in India and US (Delaware), company is a privately held Nano-biotech pharmaceutical company. Drug Discovery in 2001.
- The R&D focused outfit is led by Dr. Pawan Saharan, MS, Ph.D. (West Virginia) with over 25 years of experience in healthcare
- Advised by an eminent Board with over 200 years combined experience in Pharma /Medical, Nano- bio-technology & Dairy Tech. fields, and a worldwide research team
- 3 product lines developed, one launched - the New Generation Immune-Modulator & Broad Spectrum Anti Viral Drug (RECEPTOL®).
- Drug is effective against a broad spectrum of viral diseases/ immune disorders. Has undergone three phase of clinical trials and is ready for commercialization.
- Company manufacturing plant and R&D center located at the largest cooperative dairy in the world – AMUL, India. US Manufacturing is planned for January through June 2024
- Government Ministry of Science & Technology advanced INR 12 Crores as soft loan for setting up the manufacturing facility.

Product Lines



Demonstrate expertise, & credibility in the field of nutrition, immunity, & health. The drug is being marketed and distributed under the name RECEPTOL®



AI Knowledge Acquisition Tool (AIKAT) reduced time for initial discovery of RECEPTOL®. Virtual Speciality Hospital, Last mile delivery. Real Time Telemedicine, Emergency Services, Drug Delivery and Discovery



Hand-held AI based laser microcantilever detection of pollutants, chemical, biological, and nuclear warfare. Developed for fast, inexpensive detection of TB antigens in human blood, diagnostics of arbitrary bio-chemical compounds in bodily fluids. Efficient Diagnosis and Prevention of Disease

Vision

HEALTH FOR ALL via affordable and effective healthcare

Mission

Develop & manufacture cost effective, safe products for prevention & treatment of all communicable & immune disorders

Goal

Helping 8 billion lives globally

Global Health Problems – Millions Suffer from



Cancer



Infectious Disease



Medical Unmet Needs

INDIAN SOLUTION TO GLOBAL HEALTH PROBLEMS

What if there was a way to treat all immunity disorders via

RECEPTOL®, not only strengthens body's own immune system but also prevents recurrent infections in Cancer, Infectious Disease, environmental and war connected health issues, & help find solutions to medical unmet needs.

2018 Nobel Prize for Cancer Immunotherapy supports RECEPTOL®
Claims per US & EU granted Patents for All Immunity disorders

Medicine Laureate Dr. Tasuku Honjo
Professor at Kyoto University.

Medicine Laureate Dr. James P. Allison
Chairman of immunology at the University
of Texas M.D. Anderson Cancer Center

Identified Checkpoint PD-1

Identified Checkpoint CTLA-4

T-cells can identify and kill infected, damaged or cancerous cells. Cancer cells can avoid destruction by taking advantage of a switch on the T-cell called an immune checkpoint. The checkpoint can shut down the T-cell and suppress the immune response, allowing the cancer to grow unchecked. The checkpoint discoveries by Dr. Allison and Dr. Honjo made it possible to develop drugs that would stop the checkpoints from working, so that the T-cells would be free to fight cancer, taking the brakes off the immune system.

RECEPTOL®

**Cell surface checkpoint inhibitors can physically block the checkpoint,
which frees the immune system to attack the cancer**

Innovations in Pharma, Healthcare & Diagnostics

PANDEMICS

ENVIRONMENT

WAR ISSUES

PROBLEM

Immunity Drug



RECEPTOL[®]
Immune Booster &
Cancer Checkpoint
Blocker

Lab on Chip



Handheld AI-based
laser microcantilever
detection of pollutants
&
Chemical, Biological,
and Nuclear Warfare

Hospital on Chip




Global Hub
Last Mile Delivery
Telemedicine
Teliagnosis

AI - Virtual Hospital

Pharma, CRO, Drug
Discovery

Globally Patented SOLUTIONS

Founders



Dr. George Wald

- 2 Nobel Prizes
- Vit A Inventor
- Biomix Advisor



Joseph Weizenbaum

- Father of AI
- Inventor of 1st Robot
- Biomix Advisor



Dr. Pawan Saharan

- Biomix Founder
- Inventor:
RECEPTOL®
- Patent holder for
58/108 Disease
Resolutions

Journey of RECEPTOL®

After 18 years of research, we have successfully isolated Nano peptides from bovine colostrum and conducted global clinical studies on subjects suffering from Cancer, Infectious Disease viz Covid, AIDS, Swine Flu & Immunity diseases especially to address medical unmet needs based on stand alone AIDS therapy model.

RECEPTOL® Active ingredients consist of Patented Nano – Informational Peptides extracted from mammalian colostrum via Ultra Nano filtration Technology having sequence id 1-8 (provided in the US Patent) & Proline Rich Poly Peptides (PRPs)
<https://patents.google.com/patent/US9249188B2/en>

RECEPTOL® clinical trials & their meta-analysis on **25,301** subjects including healthy population can be accessed at data room at www.biomix.in

Publications in leading peer reviewed medical journals on global studies just concluded are in progress with New England Journal of Medicine & Nature.


US media published a feature on the invention journey

<http://medicaltraveltoday.com/spotlight-interview-pawan-saharan-founder-ceo-biomix-network-inc/>

Government of India Health Minister recognized the release of a Book on RECEPTOL® - “The Next Wonder Drug Creating a Paradigm shift from prevention to treatment providing health for All.”

BIOMIX NETWORK LTD/INC
Engineered by Intellect. Driven by Ethics

Market Research By Glaxo IPSOS USA



LOCATION

USA, UK, & India.



SAMPLE SIZE

800 Respondents



TARGET POPULATION

Households of SEC "A" in society
consuming HFDs & FMCG
products.



PRODUCT

RECEPTOL® powder
additive

Innovation : based on consumer research conducted by IPSOS(via Glaxo) & IRMA (via Amul) on 1000 consumers families giving top box responses with very high ITP scores.

The USP against all other Colostrum products available globally is clinically proven efficacy & safety well accepted by global, US Patent granting 58 indications including all immune & viral disorders

What is RECEPTOL®?

RECEPTOL® is an innovative, single solution to boost Immunity and solves a majority of health issues related to it.

1

What it consists of ?

Active Ingredients consist of Patented Nano-Informational Peptides extracted from mammalian bovine colostrum via Ultra Nano filtration Technology with sequence id 1-8 & Proline Rich Poly Peptides (PRPs)

2



3

4

What are PRPs ?


PRPs are a class of nano-informational peptides consisting of oligo-ribonucleotides attached to a peptide molecule that act as an immunity stimulator via immune-modulation and anti-viral/bacterial activity.

How is it absorbed ?

Absorbed through the buccal mucosa or Gut
Distributed all over the body through the blood streams.

Crosses blood brain barrier to reach Pituitary gland which acts as central hub in building body's immune system naturally.

RECEPTOL® the Differentiator




RECEPTOL® Acts when All Fail

Patent No – US 9,249,188 B2

**Builds bodies own
immune system.**

**Stimulates
Tumor Necrosis
Factors NK cells
Interleukin-1 to IL-11,
Interferon- α , INF- γ .**



Mode of Action of Receptol® drastically differs from other treatments/vaccines in pipeline since it blocks entry of ALL viruses, by lockdown & augments immunomodulation in unique patterns not only for COVID-19 but all Immunity diseases including CANCER




***Source: RECEPTOL® Book released by Dr Harsh Vardhan,
Chairman WHO Board of Directors, Health and Family Welfare Minister, Government of India***



PRPs get absorbed in the blood through buccal mucosa and crosses the Blood Brain Barrier



- Radha108 (PRP) promotes differentiation of B cells, differentiation & maturation of macrophages and monocytes.
- Activates natural killer (NK) cells, cytotoxic cells of the innate immune system.
- Mitigates cell fusion and docks on HIV glycoprotein like Gp120, 180,160 and 41 mimicking receptor on the cell surface closing entry of viruses.



- Stimulates production of cytokines IL-1 to IL-11, TNF- α , INF- γ .
- Stimulates the maturation of immature thymocytes into either helper or suppressor T cells
- Radha108 also functions as a molecular signalling device which works through receptors on target cell surfaces

Electron Micrograph Showing both HIV & Coronavirus unable to infect cells via Radha108
Nona-peptides Competitive inhibition on Cell surface with viral lock down

RECEPTOL® Mode of Action in HIV/ AIDS




Figure 4. Pictures of HIV under a microscope.







Figure 5. Graphic of how RECEPTOL® protects human T-Cells.

RECEPTOL® Mode of Action in Coronavirus Scenario



Radha 108 Toll like Receptor

Radha 108 Toll like
RECEPTOL® nanopeptides
can block the attachment of
S protein of Coronavirus as
depicted above





Collection of colostrum from dairy societies across Maharashtra



Transport and freezing at -18



Processing of colostrum whey




Pre-filtration Nano-and altro filtration



Formulation



Delivery to the market



*Global Launch

Based on

1. Global Market Research by IPSOS USA
2. Indian Market Research by Institute of Rural Management
3. Phase 4 by Lupin Laboratory in India, Himalayan Health Ltd Australia, Pharm Echo Russia,

*Global Launch Strategy

Maximize revenue by

- Out licensing as a Nutraceutical to large MNCs like Unilever.
- Launch as an Immunity Booster in North America & Europe to meet Pandemic (e.g. COVID) challenge.

Globally **RECEPTOL®**

received 65 Product Patents for 58 indications in North America, Canada, EU, UK, South Africa & India with the latest being granted in February 2024

Phase I of the Clinical Trial was conducted in the United States to ascertain the safety of the product along with pre-clinical acute & sub acute studies done at National Institute of Nutrition Hyderabad.

Phase II – IV studies were conducted in Africa & India for efficacy of RECEPTOL® using AIDS as a model for all viral/immune compromised conditions

Meta Analysis including study on Allergy, Asthma, Chronic fatigue syndrome & Endometriosis were conducted in the US by doctors who dispensed the products to the patients directly. Similar studies were conducted in Australia & India on Swine Flu whose results can be seen in the links given in the History of RECEPTOL® slide

- US Patent # 9,249,188 B2, granted in February 2016, for 58 indications.
- **Canadian** Patent # 2,789,787, granted June 2018, for the same 58 indications as the US patent.
- **European** Patent # EP 2 372 571 B1, granted in March 2019, for the same 58 indications.
- **Indian** Patent # 276911, granted in April 2019, for the same 58 indications as the US patent.

Safety and Efficacy achieved by global trials:

Phase I : 12 cohort 30 days
(completely safe) in Ohio,
USA

Phase II : 30 cohort 90 days
(highly effective with no side
effects)in Nairobi – Kenya

Phase III : 60 cohort for 365
days (highly effective with no
side effects) in Rwanda,
Africa

Phase III Indian Safety & Efficacy Mono Therapy Clinical Trials with Radha 108 Nano Peptide by Government of India, Ministry of Health/National AIDS Control and Monitored by Indian Council of Medical Research/NARI* by US PATH accredited organization

Study I : 50 HIV Positive Patients at
Tertiary Care LTMG Hospital Sion, Mumbai
(Clinical trial registry #: CTRI-2012-08-002931)

Study II : 51 HIV Positive Patients at
Tertiary Care LTMG Hospital, Sion, Mumbai
(Clinical Trial registry #: CTRI-2012-09-002959)

US Product Patent Granted For 58 indications Including SARS COVID

“RECEPTOL’s unique Mode of Action led to US & EU Govt granting product patents for 58 indications: starting from the common cold, influenza, allergies, asthma, Rheumatoid Arthritis, Swine Flu, Endometriosis, Chronic Fatigue Syndrome, etc. to life threatening HIV, and Cancer with US Product Patent # 9,249,188 along with Canadian, European, Indian, South African & Singapore patents. RECEPTOL® has also been approved by Government of India for National Health Program.”

Patent No :-USA,249,188B2

Date of Patent :-Feb,02,2016



(12) United States Patent Saharan

(10) Patent No.: **US 9,249,188 B2**
(43) Date of Patent: **Feb. 2, 2016**

(54) **MAMMALIAN COLOSTRUM DERIVED NANOPETIDES FOR BROADSPECTRUM VIRAL AND RECURRENT INFECTIONS WITH A METHOD OF ISOLATION THEREOF**

(71) Applicant: Pawan Saharan, Maharashtra (IN)

(72) Inventor: Pawan Saharan, Maharashtra (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 75 days.

(21) Appl. No.: 13/945,577

(22) Filed: Mar. 18, 2013

(65) **Prior Publication Data**
US 2013/0274177 A1 Oct. 17, 2013

Related U.S. Application Data
(62) Division of application No. 13/142,327, filed as application No. PCT/IN2009/000749 on Dec. 29, 2009, now Pat. No. 8,518,454.

(30) **Foreign Application Priority Data**
Dec. 27, 2008 (IN) 13/5/MUM/2008

(51) Int. Cl.
A61K 38/00 (2006.01)
A61N 5/28 (2006.01)
A61P 31/08 (2006.01)
A61K 38/00 (2006.01)
C07K 3/00 (2006.01)
A61K 35/00 (2006.01)
C07K 5/00 (2006.01)

(52) U.S. Cl.
CPC : C07K 7/08 (2013.01); A61K 35/00 (2013.01);
A61K 38/00 (2013.01); A61K 36/00 (2013.01);
CPC : C07K 7/08; C07K 7/00 (2013.01)

(58) **Field of Classification Search**
CPC : C07K 7/08; C07K 7/00
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

5,083,878 A 11/1997 Elmslie et al.
2002/0127279 A1 9/2002 Matthews

2003/0103668 A1* 6/2003 Aronberg et al. 424/138.1
2005/0175397 A1 8/2005 Rawlin et al.
2007/0123497 A1* 9/2007 Roach 424/185.1

FOREIGN PATENT DOCUMENTS

KR 20030024002 A 4/2002
WO 01/55109 A1 8/2001
WO 01/02781 A2 8/2001
WO 2005/081628 A2 9/2005

OTHER PUBLICATIONS

Blake, Bovine Colostrum, The Forgotten Miracle, Journal of the American Holistic Veterinary Medical Association Jul. 1999, vol. 18, No. 2, pp. 39-40.*
Posters Co-operative Group Ltd, Colostrum and Infant Sales Got a Boost from SARS, 2003.*
Vernity, Colostrum is a proven, effective immune system booster, Natural News, 2003.*
Hong, S.-Y. and Qin, Z.-B., "Inhibitor of Binding 3" XP002566928, Aug. 2, 2005, retrieved from EBI Database accession No. Q4Q9P9.
Stroff W.G. et al.: "Bovine colostrum as a biologic in clinical medicine: a review—Part II: clinical studies", Int. Journal of Clinical Pharmacology and Therapeutics, vol. 46, No. 5, pp. 211-225, May 1, 2008, XP009150270, ISSN: 0946-1965.
Biselli V., Van Renssen K., Cavadonchi F., Lazzi B., Pusileo L.: "Colostrum stimulates the lymphoid tissue providing benefits in aged or immunodeficient people", Journal Biology Royal Society Open Science, Oct.-Dec., 5(4):121-4, 1991; abstract only, full-text unavailable.
Gda, S. et al.: "Insulin-like growth factor-I, GH, insulin and glucose concentrations in bovine colostrum and in plasma of dairy cows and neonatal calves around parturition", Comp. Biochem. Physiol., vol. 94A, No. 4, pp. 805-808, 1989.
Shen, F.-Y. et al.: "Effect of growth factors on cell proliferation and epithelialization in human skin", Journal of Surgical Research, vol. 59, pp. 236-244, 1995.
Examination report of corresponding European patent application 09827810.1, issued on Mar. 20, 2013.

* cited by examiner

Primary Examiner — Karlheinz R. Skowronski
Assistant Examiner — Sergio Colla
(74) **Attorney, Agent, or Firm** — Nash, Goldberg & Meyer; Tanya B. Hawkins

(57) **ABSTRACT**

The present invention relates to nanopetides isolated from mammalian colostrums with vaccine like antiviral and immunomodulator activity via binding body's own immune system and attachment inhibition on the cell surface receptors.


9 Claims, 10 Drawing Sheets

- Product is completely safe w/ no side effects after 10 years follow up
- **Sample Size:** 25,000 (Including Control Group / Healthy population)
- **Scope:** HIV, Swine Flu, Allergy/Asthma, Rheumatoid Arthritis, Endometriosis & NCD, Chronic Fatigue Syndrome
- **Hypothesis:** Weight gain is an indication of wellness and overall health. No side effects with improved QoL showcases the safety and efficacy of the product.

Conclusion:

Study reveals that RECEPTOL® oral spray therapy provides **significant efficacy & safety in all groups of patients suffering from communicable & Immunity diseases** with increased Quality of Life with increased weight gain in chronic patients.

Sr.No.	Stand Alone Receptol Therapy in Global clinical studies	No. of Patients
1	Healthy people	10,000
2	HIV Patient in USA, Africa, India	5000
3	Swine Flu	5000
4	Other Indications like allergy, asthma, Rheumatoid Arthritis, Chronic Fatigue Syndrome, Endometriosis Study etc.	5000



RECEPTOL® Efficacy & Safety - Other Indications


Allergy, Asthma, Arthritis, Diarrhoea, Fever, Fatigue-malaise, Anaemia, Endometriosis

CHANGES IN MEAN WEIGHT AMONG STUDY CASES


Duration (Weeks)	Mean weight (\pm SD) (N = 5000)
Baseline	50.41 \pm 10.03
1	50.76 \pm 10.01
2	51.11 \pm 09.94
3	51.60 \pm 09.91
4	52.15 \pm 09.91
Mean Diff. (Baseline – Wk1) (P value)	*00.35 \pm 00.57 (0.001)
Mean Diff. (Baseline – Wk2) (P value)	*00.70 \pm 01.05 (0.001)
Mean Diff. (Baseline – Wk3) (P value)	*01.19 \pm 01.77 (0.001)
Mean Diff. (Baseline – Wk4) (P value)	*01.74 \pm 01.95 (0.001)

By ANOVA

P<0.05, * Significant



- After 1 week of treatment, mean weight showed a significant rise of 0.7% from baseline.
- After 2 week of treatment, mean weight showed a significant rise of 1.4% from baseline, similar trend was observed till the end of 4 weeks.



Collaboration Options

Pharma Drug Business

1. Manufacturing capacity for commercial supply to China and APAC
2. Manufacturing AND Commercial distribution in China and APAC
3. Manufacturing capacity for commercial supply to US and Europe
4. Manufacturing AND Commercial distribution in US to Europe

Nutrient Business

1. Manufacturing capacity for nutrient supply
2. Nutrient supply network for global markets
 - a. New JV
 - b. Other CMOs
 - c. Commercial distribution partners





Emergency MMS alerts




**Tele Medicine
online 2nd opinion**



**Clinical trials CRO s/w
With MNC hosting**



**AI driven Virtual Specialty Hospital
With online medical research**



**Lab & Hospital on Chip
with Tele Diagnostic**



**GENESoft
New drug discovery s/w**

Innovation Journey - RECEPTOL® manufactured by Biomix was discovered by Dr. Pawan Saharan, MS, Ph.d. WVU, Stanford with eminent group of scientists including 2 times Nobel laureate Prof. George Wald from Harvard & Prof. Joseph Weizenbaum, MIT Founder Directors with 18 years of research and development with funding by the Department of Science & Technology, GoI.

Product - RECEPTOL®, made from Colostrum Nano-peptides helps people lead longer & healthier lives by building the body's immune system, thus aiding in prevention and cure for all communicable & Immunity diseases: Coronavirus, AIDS, Swine Flu, RA, Allergy etc.

Active Ingredients (API) - Patented Nano - Informational Peptides (Class 4 Proline Rich Poly Peptides & Radha108).

Mode of Action - RECEPTOL® gets absorbed in the blood through the buccal mucosa and crosses the Blood-Brain-Barrier. It stimulates maturation of immature thymocytes into either helper or suppressor T cells. It stimulates secretion of Tumour Necrosis Factor & cytokines IL-1 to IL-11, INF-a, INF-y. Activates Natural Killer (NK) Cells, cytotoxic cells of the innate immune system by 5 times.

Indications – Immunity Enhancer for Recurrent infections in Cancer, Infectious Disease & medical unmet needs viz rare immunity disorders.

USP- Innovative with common Mode of Action for all viral infections, affordable, globally patented, broad spectrum anti-viral, immunomodulator, easy to administer, 100% natural with side effects, can be consumed by all and has no age or sex barriers.

Global Patents - US Product Patent # 9,249,188, Canadian, European, Indian, South African & Singapore for 58 diseases.

Market Research: Glaxo Consumer Healthcare conducted Global Consumer Research via IPSOS showing intention to purchase score of 97% of all medical and health professionals.

Global Clinical Studies - Global Safety & Efficacy monotherapy on AIDS & other indications: Highly efficacious and free of all side effects.

Goal - Helping 8 billion lives via safe, affordable and effective treatment & prevention of All communicable disease.



To meet the goal post of our common priority Vision in preventing current and future pandemics, we propose to use 21st Century Technology Innovation RECEPTOL® in improving health and wellbeing of more than an 8 billion people in India and abroad with Mumbai as a hub in tie up with the dairy and pharmaceutical industry.



We are looking for a 25 years business association in manufacturing and marketing of RECEPTOL® finish products by dairy and pharma industry to prevent all infections and enhance the health, nutrition, and general wellbeing of the common man; using the best of innovation and technology in a sustainable manner leading to drastic reduction in child & female mortality rate in India and abroad by over 50%.



Biomix will bring the proprietary technology developed in last 15 years with an investment of US dollar \$150M in collaboration with Pharma.

Potential Revenues:	USA	Year 1: USD 1 Billion	Year 5: USD >5 Billion.
	Worldwide	Year 5: USD 7 Billion	Year 5: USD >25 Billion

Long COVID, new pandemics, environmental and war connected health challenges upscale the revenues estimates, as per the RECEPTOL® roadmap.

Founder CEO

Dr. Pawan Saharan, MS, Ph.D. (JNU, WVU)
AMP (ASCI in tie up with Harvard business school)
Best US graduate student scientist award by AAAS with
fellowship at Stanford Medical Centre, Palo Alto, CA.
Email id: biomix108@gmail.com / drpawan@biomix.in

Clinical Director

Prof. Dr. Ali Irani - Ph.D. DPT (Spain), Head of Department
Physiotherapy & Sports Medicine, Nanavati Hospital, Mumbai
Former Physiotherapist of Indian Cricket Team (12 years)

Project Director

Amitabh Thakore, B. Tech., MBA (IIMA), MS (USA)

Business Advisor

Ranjit Shahani BE IIT, MBA Jamnalal Bajaj
Chairman Novartis South Asia

Founder Directors include:

Late Prof George Wald, Harvard Medical Centre 2 times Nobel Prize Winner
Prof Joseph Weizenbaum, Father of AI Founder Chair Robotics Comp science Dept. MIT

Medical Directors

Dr. S.H. Advani, MD, FICP, FNAMS
Oncologist & President - Asian Cancer Society
Padamvibhusan awardee by President of India

Dr. Sushil Indoria , MD
Medical Director Life care Hospital, Thane

Dr. Sandhya Saharan, MD, DGO,
Gynecologist and IVF specialist

Marketing Advisor

Sumeet Arora, COO YUM Group Companies in Canada

Business Development Manager

Hemangi Saharan, MBA
University of North Carolina, Chapel Hills, NC, USA

Business Development Manager

Nicolas Corzo, Master in Strategic Management
Strategic Management and Partnerships (Global)